MedTrace Logo

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

NCT05180097 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-02-02

No results posted yet for this study

Summary

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

Conditions

Interventions

DRUG

Gemcitabine

1000mg/m2 IV, 30 mins D1, D8

DRUG

Dexamethasone

40mg daily PO, D1-D4

DRUG

Cisplatin

75mg/m2 IV, 1 hour, D1

DRUG

Brentuximab vedotin

1.8 mg/kg IV, 30 mins, Q21 days

DRUG

Pembrolizumab

200mg IV, 30 mins, Q 21 days

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Australasian Leukaemia and Lymphoma Group

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Kerry Savage · BCCA-Vancouver Cancer Centre

  • John Kuruvilla · University Health Network, Princess Margaret Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180097 on ClinicalTrials.gov